<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940705-2-00220</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Appendix M&hyph;I&hyph;B&hyph;2&hyph;a. Delivery System.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Appendix M&hyph;I&hyph;B&hyph;2&hyph;a&hyph;(1). What cells are the intended target cells of recombinant  <!-- PJG 0012 frnewline --> DNA? What target cells are to be treated ex vivo and returned to the patient,  <!-- PJG 0012 frnewline --> how will the cells be characterized before and after treatment? What is the  <!-- PJG 0012 frnewline --> theoretical and practical basis for assuming that only the target cells will  <!-- PJG 0012 frnewline --> incorporate the DNA?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;B&hyph;2&hyph;a&hyph;(2). Is the delivery system efficient? What percentage of the  <!-- PJG 0012 frnewline --> target cells contain the added DNA?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;B&hyph;2&hyph;a&hyph;(3). How is the structure of the added DNA sequences  <!-- PJG 0012 frnewline --> monitored and what is the sensitivity of the analysis? Is the added DNA  <!-- PJG 0012 frnewline --> extrachromosomal or integrated? Is the added DNA unrearranged?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;B&hyph;2&hyph;a&hyph;(4). How many copies are present per cell? How stable is  <!-- PJG 0012 frnewline --> the added DNA both in terms of its continued presence and its structural stability?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Appendix M&hyph;I&hyph;B&hyph;2&hyph;b. Gene Transfer and Expression.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Appendix M&hyph;I&hyph;B&hyph;2&hyph;b&hyph;(1). What animal and cultured cell models were used in  <!-- PJG 0012 frnewline --> laboratory studies to assess the in vivo and in vitro efficacy of the gene transfer  <!-- PJG 0012 frnewline --> system? In what ways are these models similar to and different from the proposed  <!-- PJG 0012 frnewline --> human treatment?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;B&hyph;2&hyph;b&hyph;(2). What is the minimal level of gene transfer and/or  <!-- PJG 0012 frnewline --> expression that is estimated to be necessary for the gene transfer protocol to be  <!-- PJG 0012 frnewline --> successful in humans? How was this level determined?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;B&hyph;2&hyph;b&hyph;(3). Explain in detail all results from animal and cultured cell  <!-- PJG 0012 frnewline --> model experiments which assess the effectiveness of the delivery system (see  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;B&hyph;2&hyph;a) in achieving the minimally required level of gene transfer and  <!-- PJG 0012 frnewline --> expression (see Appendix M&hyph;I&hyph;B&hyph;2&hyph;b&hyph;(2)).  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;B&hyph;2&hyph;b&hyph;(4). To what extent is expression only from the desired gene  <!-- PJG 0012 frnewline --> (and not from the surrounding DNA)? To what extent does the insertion modify  <!-- PJG 0012 frnewline --> the expression of other genes?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;B&hyph;2&hyph;b&hyph;(5). In what percentage of cells does expression from the  <!-- PJG 0012 frnewline --> added DNA occur? Is the product biologically active? What percentage of normal  <!-- PJG 0012 frnewline --> activity results from the inserted gene?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;B&hyph;2&hyph;b&hyph;(6). Is the gene expressed in cells other than the target cells?  <!-- PJG 0012 frnewline --> If so, to what extent?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Appendix M&hyph;I&hyph;B&hyph;2&hyph;c. Retrovirus Delivery Systems.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Appendix M&hyph;I&hyph;B&hyph;2&hyph;c&hyph;(1). What cell types have been infected with the retroviral  <!-- PJG 0012 frnewline --> vector preparation? Which cells, if any, produce infectious particles?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;B&hyph;2&hyph;c&hyph;(2). How stable are the retroviral vector and the resulting  <!-- PJG 0012 frnewline --> provirus against loss, rearrangement, recombination, or mutation? What  <!-- PJG 0012 frnewline --> information is available on how much rearrangement of recombination with  <!-- PJG 0012 frnewline --> endogenous or other viral sequences is likely to occur in the patient's cells? What  <!-- PJG 0012 frnewline --> steps have been taken in designing the vector to minimize instability or variation?  <!-- PJG 0012 frnewline --> What laboratory studies have been performed to check for stability, and what is the  <!-- PJG 0012 frnewline --> sensitivity of the analyses?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;B&hyph;2&hyph;c&hyph;(3). What laboratory evidence is available concerning  <!-- PJG 0012 frnewline --> potential harmful effects of the transfer (e.g., development of neoplasia, harmful  <!-- PJG 0012 frnewline --> mutations, regeneration of infectious particles, or immune responses)? What steps  <!-- PJG 0012 frnewline --> will be taken in designing the vector to minimize pathogenicity? What laboratory  <!-- PJG 0012 frnewline --> studies have been performed to check for pathogenicity, and what is the sensitivity  <!-- PJG 0012 frnewline --> of the analyses?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;B&hyph;2&hyph;c&hyph;(4). Is there evidence from animal studies that vector DNA  <!-- PJG 0012 frnewline --> has entered untreated cells, particularly germ-line cells? What is the sensitivity of  <!-- PJG 0012 frnewline --> the analyses?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;B&hyph;2&hyph;c&hyph;(5). Has a protocol similar to the one proposed for a clinical  <!-- PJG 0012 frnewline --> trial been conducted in non-human primates and/or other animals? What were  <!-- PJG 0012 frnewline --> the results? Specifically, is there any evidence that the retroviral vector has  <!-- PJG 0012 frnewline --> recombined with any endogenous or other viral sequences in the animals?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Appendix M&hyph;I&hyph;B&hyph;2&hyph;d. Non-Retrovirus Delivery/Expression Systems.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> If a non-retroviral delivery system is used, what animal studies have been  <!-- PJG 0012 frnewline --> conducted to determine if there are pathological or other undesirable  <!-- PJG 0012 frnewline --> consequences of the protocol (including insertion of DNA into cells other than  <!-- PJG 0012 frnewline --> those treated, particularly germ-line cells)? How long have the animals been  <!-- PJG 0012 frnewline --> studied after treatment? What safety studies have been conducted? (Include data  <!-- PJG 0012 frnewline --> about the level of sensitivity of such assays.)  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Appendix M&hyph;I&hyph;B&hyph;3. Clinical Procedures, Including Patient Monitoring.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Describe the treatment that will be administered to patients and the diagnostic  <!-- PJG 0012 frnewline --> methods that will be used to monitor the success or failure of the treatment. If  <!-- PJG 0012 frnewline --> previous clinical studies using similar methods have been performed by yourself or  <!-- PJG 0012 frnewline --> others, indicate their relevance to the proposed study. Specifically:  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            